Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

148
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
148
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

220
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
220
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

107
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
107
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

91
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
91
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

257
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
257
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

89
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
89

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Escalation to transplantation in refractory stone heart syndrome: a case report of advanced mechanical circulatory support failure.

Journal of cardiothoracic surgery·2026
Same author

Machine Learning Based Prediction of Hospital Mortality in Post-Cardiotomy Cardiogenic Shock with Mechanical Support.

ESC heart failure·2026
Same author

Cardiac microcurrent therapy in heart failure: Mechanistic rationale, early clinical evidence, and future directions.

Heart failure reviews·2026
Same author

DIGIT-HF: Results From the Win Ratio Analyses.

Circulation. Heart failure·2026
Same author

Pathophysiology, prevention, and management of coronary microvascular obstruction.

European heart journal·2026
Same author

Phosphatidylserine-Dependent Clearance of Damaged Red Blood Cells by Liver Sinusoidal Endothelial Cells in Alcohol-Related Liver Disease.

Biology·2026

Related Experiment Video

Updated: Nov 18, 2025

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
08:47

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes

Published on: December 16, 2022

2.7K

Cardio-microcurrent device for chronic heart failure: first-in-human clinical study.

Dragana Kosevic1, Dominik Wiedemann2, Petar Vukovic1

  • 1Cardiovascular Institute Dedinje Belgrade, Belgrade, Serbia.

ESC Heart Failure
|February 9, 2021
PubMed
Summary

Chronic electrical microcurrent therapy is safe and effective for heart failure patients, rapidly improving cardiac function, heart size, and quality of life. This novel treatment shows significant promise for managing heart conditions.

Keywords:
Electric potential gradientElectrical microcurrentElectro-osmosisHeart failure

More Related Videos

Advanced Cardiac Rhythm Management by Applying Optogenetic Multi-Site Photostimulation in Murine Hearts
08:43

Advanced Cardiac Rhythm Management by Applying Optogenetic Multi-Site Photostimulation in Murine Hearts

Published on: August 26, 2021

2.7K
Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment
08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

7.2K

Related Experiment Videos

Last Updated: Nov 18, 2025

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
08:47

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes

Published on: December 16, 2022

2.7K
Advanced Cardiac Rhythm Management by Applying Optogenetic Multi-Site Photostimulation in Murine Hearts
08:43

Advanced Cardiac Rhythm Management by Applying Optogenetic Multi-Site Photostimulation in Murine Hearts

Published on: August 26, 2021

2.7K
Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment
08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

7.2K

Area of Science:

  • Cardiology
  • Biomedical Engineering
  • Medical Devices

Background:

  • Current heart failure treatments often rely on electrical pulses.
  • Myocardial performance is influenced by electric potential gradients, which can be disrupted in structural heart diseases.

Purpose of the Study:

  • To investigate the feasibility, safety, and efficacy of chronic electrical microcurrent application to the heart.
  • To gather data for designing a future Phase II clinical trial.

Main Methods:

  • A pilot study involving 10 patients with NYHA Class III heart failure and LVEF <35%.
  • Surgical implantation of a device to deliver constant cardiac microcurrent.
  • Assessment of left ventricular ejection fraction (LVEF), cardiac dimensions, 6-minute walk test, NYHA classification, and quality of life over 6 months.

Main Results:

  • Microcurrent application was feasible and safe, with no adverse events.
  • Significant improvements observed in LVEF, cardiac dimensions, and walking distance (P < 0.005).
  • NYHA classification improved from Class III to Class I/II for all patients within days, with quality of life scores also significantly increasing.

Conclusions:

  • Chronic cardiac microcurrent therapy is a safe and feasible treatment for heart failure.
  • The therapy demonstrates rapid and sustained improvements in cardiac function, heart size, NYHA class, and quality of life.